Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the quarter ended December 31, 2018, and the six-month period ended December 31, 2018. The company is a foreign private issuer based in Australia.
Key Financial Metrics
| Metric | Current Quarter ($A'000) | Year to Date ($A'000) |
|---|---|---|
| Net Cash Used in Operating Activities | (3,983) | (7,247) |
| Net Cash from Financing Activities | - | 159 |
| Cash and Cash Equivalents (End of Period) | 8,383 | 8,383 |
| Payments to Directors | 350 | - |
| Interest Received | 29 | 68 |
Revenue: The filing does not provide a clear value for revenue or receipts from customers; the line item is listed as zero or not applicable for the period.
Profit/Loss: The filing does not provide a clear value for net profit or loss; only cash flow data is presented.
Debt: No loan facilities or borrowings were drawn at quarter end.
Material Changes and Cash Flow Analysis
- Operating Cash Burn: The company utilized $3.98 million in cash for operations in the current quarter, with significant outflows for research and development ($2.45 million) and staff costs ($0.94 million).
- Financing Activity: During the six-month period, the company raised $166,000 from share issues, net of $7,000 in transaction costs. No financing activity occurred in the current quarter alone.
- Liquidity Position: Cash and cash equivalents decreased from $12.28 million at the end of the previous quarter to $8.38 million at the end of the current quarter, primarily due to operating outflows.
Outlook, Risks, and Contingencies
- Capital Raise: As announced on December 28, 2018, the company entered into a securities purchase agreement with Life Biosciences LLC to raise up to approximately A$44.5 million, subject to shareholder approval.
- Estimated Outflows: Management estimates total cash outflows for the next quarter to be $5.37 million, driven by $3.5 million in R&D and $0.95 million in staff costs.
- Risks: The filing does not explicitly detail specific risks beyond the standard requirement for shareholder approval for the proposed capital raise.
Investor Verification Checklist
- Verify the status of the proposed A$44.5 million capital raise with Life Biosciences LLC and whether shareholder approval has been obtained.
- Confirm the company's runway given the current cash balance of $8.38 million against estimated quarterly burn rates exceeding $5 million.
- Review the discrepancy between the metadata company name (Alteryx Therapeutics) and the filing registrant (Prana Biotechnology).
- Monitor the timeline for the next quarterly report to assess if the cash burn rate accelerates without the new funding.